Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BHC NASDAQ:MOR NASDAQ:RAPP NASDAQ:RYTM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHCBausch Health Cos$6.47-0.2%$6.92$4.25▼$9.85$2.40B0.482.60 million shs1.61 million shsMORMorphoSys$18.96$18.96$4.18▼$19.50$2.86B1.21.02 million shsN/ARAPPRapport Therapeutics$27.97+5.2%$18.48$6.43▼$42.27$1.02B0.71363,512 shs836,740 shsRYTMRhythm Pharmaceuticals$100.64+1.5%$95.98$45.90▼$106.52$6.68B2.23661,483 shs566,721 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHCBausch Health Cos0.00%-3.57%-12.42%-2.84%-21.43%MORMorphoSys0.00%0.00%0.00%0.00%0.00%RAPPRapport Therapeutics0.00%+0.87%+50.82%+133.86%+24.66%RYTMRhythm Pharmaceuticals0.00%+3.23%-3.87%+56.92%+93.11%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHCBausch Health Cos$6.47-0.2%$6.92$4.25▼$9.85$2.40B0.482.60 million shs1.61 million shsMORMorphoSys$18.96$18.96$4.18▼$19.50$2.86B1.21.02 million shsN/ARAPPRapport Therapeutics$27.97+5.2%$18.48$6.43▼$42.27$1.02B0.71363,512 shs836,740 shsRYTMRhythm Pharmaceuticals$100.64+1.5%$95.98$45.90▼$106.52$6.68B2.23661,483 shs566,721 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHCBausch Health Cos0.00%-3.57%-12.42%-2.84%-21.43%MORMorphoSys0.00%0.00%0.00%0.00%0.00%RAPPRapport Therapeutics0.00%+0.87%+50.82%+133.86%+24.66%RYTMRhythm Pharmaceuticals0.00%+3.23%-3.87%+56.92%+93.11%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBHCBausch Health Cos 2.00Hold$9.0039.10% UpsideMORMorphoSys 0.00N/AN/AN/ARAPPRapport Therapeutics 3.25Buy$35.3326.33% UpsideRYTMRhythm Pharmaceuticals 3.06Buy$106.645.96% UpsideCurrent Analyst Ratings BreakdownLatest RAPP, BHC, RYTM, and MOR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/29/2025RYTMRhythm PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$100.00 ➝ $110.009/25/2025RYTMRhythm PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform9/25/2025RYTMRhythm PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$135.00 ➝ $142.009/24/2025RYTMRhythm PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$109.00 ➝ $122.009/24/2025RYTMRhythm PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$105.00 ➝ $138.009/16/2025RAPPRapport TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$44.009/12/2025RAPPRapport TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy9/8/2025RAPPRapport TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$31.00 ➝ $34.008/7/2025RYTMRhythm PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$80.00 ➝ $100.008/6/2025RAPPRapport TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$31.008/6/2025RYTMRhythm PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$119.00 ➝ $120.00(Data available from 9/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBHCBausch Health Cos$9.63B0.25$7.70 per share0.84($0.89) per share-7.27MORMorphoSys$238.28M11.99N/AN/A$0.35 per share54.17RAPPRapport TherapeuticsN/AN/AN/AN/A$8.35 per shareN/ARYTMRhythm Pharmaceuticals$130.13M51.37N/AN/A$0.35 per share287.54Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBHCBausch Health Cos-$46M$0.2624.891.39N/A0.99%-852.36%5.25%10/29/2025 (Estimated)MORMorphoSys-$205.35M-$3.48N/AN/AN/A-226.79%-694.31%-22.55%N/ARAPPRapport Therapeutics-$78.31M-$2.50N/AN/AN/AN/A-29.99%-28.64%11/6/2025 (Estimated)RYTMRhythm Pharmaceuticals-$260.60M-$3.01N/AN/AN/A-117.13%-1,831.43%-48.33%11/4/2025 (Estimated)Latest RAPP, BHC, RYTM, and MOR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025RAPPRapport Therapeutics-$0.87-$0.75+$0.12-$0.75N/AN/A8/5/2025Q2 2025RYTMRhythm Pharmaceuticals-$0.66-$0.75-$0.09-$0.75$43.72 million$48.50 million7/30/2025Q2 2025BHCBausch Health Cos$0.97$0.90-$0.07$0.40$2.47 billion$2.57 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBHCBausch Health CosN/AN/AN/AN/AN/AMORMorphoSysN/AN/AN/AN/AN/ARAPPRapport TherapeuticsN/AN/AN/AN/AN/ARYTMRhythm PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBHCBausch Health Cos141.901.310.98MORMorphoSys4.981.381.38RAPPRapport TherapeuticsN/A22.7522.75RYTMRhythm PharmaceuticalsN/A2.792.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBHCBausch Health Cos78.65%MORMorphoSys18.38%RAPPRapport TherapeuticsN/ARYTMRhythm PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipBHCBausch Health Cos19.97%MORMorphoSys0.05%RAPPRapport Therapeutics13.57%RYTMRhythm Pharmaceuticals6.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBHCBausch Health Cos20,700370.35 million296.39 millionOptionableMORMorphoSys730150.62 million150.55 millionNot OptionableRAPPRapport TherapeuticsN/A36.50 million31.55 millionN/ARYTMRhythm Pharmaceuticals14066.42 million62.37 millionOptionableRAPP, BHC, RYTM, and MOR HeadlinesRecent News About These CompaniesRhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price Expected to Rise, JMP Securities Analyst SaysSeptember 27 at 2:59 AM | americanbankingnews.comJMP Securities Maintains Rhythm Pharmaceuticals (RYTM) Market Outperform RecommendationSeptember 26 at 6:03 AM | msn.comRhythm Pharmaceuticals price target raised to $142 from $135 at Citizens JMPSeptember 25, 2025 | msn.comJMP Securities Issues Positive Forecast for Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock PriceSeptember 25, 2025 | marketbeat.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives $101.57 Average Price Target from AnalystsSeptember 25, 2025 | americanbankingnews.comRhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price Expected to Rise, The Goldman Sachs Group Analyst SaysSeptember 25, 2025 | americanbankingnews.comRhythm Pharmaceuticals price target raised to $122 from $109 at Morgan StanleySeptember 24, 2025 | msn.comRhythm Pharmaceuticals, Inc. (RYTM) Discusses On Commercial Readiness For Acquired Hypothalamic Obesity Event Call (Transcript)September 24, 2025 | seekingalpha.comRhythm Pharmaceuticals, Inc. - Special CallSeptember 24, 2025 | seekingalpha.comRhythm Pharmaceuticals, Inc. (RYTM) Discusses on Commercial Readiness for Acquired Hypothalamic Obesity EventSeptember 24, 2025 | seekingalpha.comRhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Raised to $138.00 at The Goldman Sachs GroupSeptember 24, 2025 | marketbeat.com3 Stocks That May Be Undervalued By Up To 49%September 23, 2025 | finance.yahoo.comRhythm Pharmaceuticals, Inc. $RYTM Shares Sold by Wedge Capital Management L L P NCSeptember 23, 2025 | marketbeat.comAssenagon Asset Management S.A. Has $15.04 Million Position in Rhythm Pharmaceuticals, Inc. $RYTMSeptember 23, 2025 | marketbeat.comToth Financial Advisory Corp Takes $632,000 Position in Rhythm Pharmaceuticals, Inc. $RYTMSeptember 22, 2025 | marketbeat.com2 Under-the-Radar Stocks That Could SoarSeptember 21, 2025 | fool.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Given Consensus Recommendation of "Buy" by BrokeragesSeptember 20, 2025 | marketbeat.comVoya Investment Management LLC Cuts Stock Holdings in Rhythm Pharmaceuticals, Inc. $RYTMSeptember 20, 2025 | marketbeat.comStrs Ohio Invests $980,000 in Rhythm Pharmaceuticals, Inc. $RYTMSeptember 19, 2025 | marketbeat.comHarbor Capital Advisors Inc. Grows Stake in Rhythm Pharmaceuticals, Inc. $RYTMSeptember 18, 2025 | marketbeat.comE. Ohman J or Asset Management AB Purchases Shares of 8,213 Rhythm Pharmaceuticals, Inc. $RYTMSeptember 18, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines2 Data Center REITs That Look Good in Any PortfolioBy Sam Quirke | September 8, 2025Oracle Has Spoken: AI Changes EverythingBy Thomas Hughes | September 10, 20253 Hot Tech Stocks With Bullish Charts and Ample UpsideBy Thomas Hughes | September 15, 2025What NVIDIA’s Big Bet on Rival Quantinuum Means for D-Wave StockBy Nathan Reiff | September 8, 2025Uranium Energy Stock Has Momentum—and More Upside AheadBy Gabriel Osorio-Mazilli | September 16, 2025RAPP, BHC, RYTM, and MOR Company DescriptionsBausch Health Cos NYSE:BHC$6.47 -0.01 (-0.15%) Closing price 03:59 PM EasternExtended Trading$6.47 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.MorphoSys NASDAQ:MOR$18.96 0.00 (0.00%) As of 09/26/2025MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.Rapport Therapeutics NASDAQ:RAPP$27.97 +1.38 (+5.19%) Closing price 04:00 PM EasternExtended Trading$27.96 0.00 (-0.02%) As of 04:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.Rhythm Pharmaceuticals NASDAQ:RYTM$100.64 +1.48 (+1.49%) Closing price 04:00 PM EasternExtended Trading$100.42 -0.22 (-0.22%) As of 04:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Top-Rated Dividend Growth Stocks to Buy in October Top Insider Buys and Sells From September: Buy, Sell, or Hold? MarketBeat Week in Review – 09/22 - 09/26 Get Exposure to Millennials' Purchasing Power With This ETF Beam Global Gets Buy Rating With 101% Upside Potential Institutional Buying Sets a High Floor for Microsoft Stock High-Momentum ETFs to Mine for Gold, Silver, and Bitcoin ASML Is a Hidden Gem in This Technology Rally, a Catch Up Play Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
